Skip to content

Compare medicines

Put up to three medicines side by side. Useful for alternatives in the same class, or for seeing how two very different treatments differ.

Attribute
In shortFirst-generation EGFR tablet for mutated lung cancer.EGFR tablet for lung cancers with EGFR mutations.
Body systemCancerCancer
Drug classTyrosine kinase inhibitorsTyrosine kinase inhibitors
SupplyPrescription onlyWHO essential medicinePrescription onlyWHO essential medicine
Main usesEGFR-mutated non-small-cell lung cancerEGFR-mutated non-small-cell lung cancer, Pancreatic cancer (with gemcitabine)
How it worksBlocks a growth signal in EGFR-mutated lung cancer.Blocks a growth signal in EGFR-mutated lung cancer.
Starts workingDepends on the cancer and regimenDepends on the cancer and regimen
Half-lifeAbout 48 hoursAbout 36 hours
Typical adult doseDosed by your cancer team according to the treatment protocol.Dosed by your cancer team according to the treatment protocol.
FormsTabletTablet
Common side effectsAcne-like rash, Diarrhoea, Dry skin, Nausea, TirednessAcne-like rash, Diarrhoea, Dry skin, Loss of appetite, Tiredness
Serious side effectsLung inflammation, Liver injury, Bowel perforationLung inflammation, Liver failure, Bowel perforation, Eye problems
Don't take ifPregnancy; Severe liver impairmentPregnancy; Severe liver impairment
AlcoholBest to limit. Alcohol may add to liver strain.Best to limit. Alcohol may add to liver strain.
PregnancyUsually avoidedAvoid.Usually avoidedAvoid.
BreastfeedingUsually avoidedAvoid.Usually avoidedAvoid.
In use since——
Brand namesUnited States: IressaUnited Kingdom: IressaIndia: Iressa, Gefitinib (generic)United States: TarcevaUnited Kingdom: TarcevaIndia: Tarceva, Erlonib, Erlotinib (generic)
Legal statusUnited States: Prescription onlyUnited Kingdom: Prescription-only medicine (POM)India: Schedule HUnited States: Prescription onlyUnited Kingdom: Prescription-only medicine (POM)India: Schedule H
ATC codeL01EB01L01EB02

Taken together

No interaction between these medicines is recorded in the atlas.

Open in the interaction checker